tbuckley/cabot-search huggingface dataset:
SAT0696 Associations between antibiotics for non-tuberculous mycobacterial infection and incident sjÖgren’s syndrome: a nationwide, population-based case-control study
Authors: H.-H. Chen, W.-C. Chao
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> We recently reported an association between Sjögren's syndrome (SS) and prior nontuberculous mycobacterial (NTM) infection which was defined as having a diagnosis of NTM with concurrent combinational antibiotics therapy for NTM infection. However, whether the increased risk of SS was attributed to NTM infection or antibiotics used to treatment NTM infection was unknown. <h3>Objectives</h3> To address the association between use of antibiotics which can be used to treat NTM infection and the risk of newly diagnosed SS. <h3>Methods</h3> Using a nationwide, population-based, claims dataset, 5751 newly diagnosed SS were identified, and we further excluded those (n=198) having a history of confirmed or suspected mycobacterial infection to avoid the confounding effect of NTM infection-associated incident SS as we previously identified. A total of 5,553 SS cases were enrolled and compared them with 83 295 non-SS controls matched (1:15) for age, sex, and their year of first SS diagnosis date. The association between the risk of incident SS and antibiotics was determined by calculating odds ratios (ORs) with 95% confidence intervals (CIs) using conditional logistic regression analysis. <h3>Results</h3> After adjusting for potential confounders, the risk of SS was increased in patients treated with new macrolides (aOR 1.95, 95% CI 1.80–2.11), fluoroquinolones (aOR 1.52, 95% CI 1.41–1.64), and tetracyclines (aOR 1.69, 95% CI 1.59–1.79) compared with those in non-SS controls after adjusting for CCI, bronchiectasis and <i>Helicobacter pylori</i> infection. Notably, we found that the association was consistent among each antibiotic in these three groups of antibiotics. In contrast to these three groups of antibiotics, usage of amikacin was found to have a negative association with incident SS (aOR 0.68, 95% CI 0.53–0.87). <h3>Conclusions</h3> New macrolides, fluoroquinolones and tetracyclines were associated with a higher incidence of SS, whereas usage of amikacin had a negative correlation. These findings indicated the need for vigilance of SS in prescribing these antibiotics to treat NTM and other infectious diseases and warrant further mechanistic studies. <h3>References</h3> [1] Mor A, Pillinger MH, Wortmann RL, Mitnick HJ. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum2008;38(3):249–64. [2] Chao WC, Lin CH, Lia TL, Chen YM, Chen DY, Chen HH. Association between a history of mycobacterial infection and the risk of newly diagnosed Sjogren's syndrome: a nationwide, population-based case-control study. PLoS ONE2017;12(5):e0176549. <h3>Acknowledgements</h3> We thank for the statistical work by Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan, ROC. <h3>Disclosure of Interest</h3> None declared
Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model
Authors: Shih-Shih Chen, Jeffery Lorne Kutok, Gerardo Ferrer, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Jacqueline C Barrientos, David T. Weaver, Jonathan A Pachter, Kanti R Rai, Nicholas Chiorazzi
Journal: Blood (2018)
FRI0473 Mpo-anca positivity is related to interstitial lung disease in systemic sclerosis
Authors: Y. Ichimura, Y. Kawaguchi, K. Takagi, A. Tochimoto, T. Higuchi, H. Yamanaka
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Recently, there were several reports that patients with systemic sclerosis (SSc) showed acute renal failure with anti-neutrophil cytoplasmic antibody (ANCA) positivity. On the other hand, it is also reported that 7%–13% of patients with SSc revealed myeloperoxidase-ANCA (MPO-ANCA) positivity without vasculitis manifestation in 1990s, but their clinical characteristics were unclear. It is also unknown whether ANCA positivity leads to AAV or not in patients with SSc. It is important for physicians to clarify the characteristics of SSc patients with ANCA positivity, and answer the question whether they will shift ANCA-associated vasculitis (AAV). <h3>Objectives</h3> To assess the prevalence of ANCA positive patients with SSc, and clarify the characteristics of these patients. <h3>Methods</h3> We enrolled the 333 consecutive patients with SSc who visited our clinic during October 2014 to September 2015, all of who were checked MPO-ANCA using fluorescent-enzyme immune-assay. Clinical manifestation and laboratorial data were obtained from medical chart. The data were assessed by chai-square analysis and Welch's t test. <h3>Results</h3> Two patients were diagnosed AAV before October 2014. Eight patients (2.4%) revealed MPO-ANCA positivity without vasculitis manifestation. All of MPO-ANCA positive patients were female, and mean age and disease duration were 61.1 years old and 17.2 years, respectively, and there's no statistically significant differences comparing MPO-ANCA negative patients. As a result of evaluating clinical manifestations, we found that patients with MPO-ANCA positivity more frequently had interstitial lung disease than patients without MPO-ANCA positivity (87.5% vs. 36.7%, p&lt;0.01). The clinical characteristics of 8 patients were shown in table 1. Only one patient out of 8 patients with MPO-ANCA positivity newly diagnosed AAV during mean of 33 months follow-up period. <h3>Conclusions</h3> The prevalence of MPO-ANCA positivity in SSc patients were lower than previous reports. MPO-ANCA positivity may be related to interstitial lung disease in SSc. MPO-ANCA positive patient may occasionally reveal AAV in the future, and careful observation are needed. <h3>Disclosure of Interest</h3> None declared
Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)
Authors: Anuraag Kansal, Mark Du, Oscar Herrera-Restrepo, Robert Leipold, Robert J. Ryan, Arthur C. Louie, Karen Chung
Journal: Blood (2017)
Abstract 12147: Heart Failure With Preserved and Reduced Ejection Fraction in Middle Eastern Arab and South Asian Patients Hospitalized in a Middle-Eastern Country (1991-2013)
Authors: Amar M Salam, Hajar AlBinali, Rajvir Singh, Awad Al-Qahtani, Nidal Asaad, Jassim Al-Suwaidi
Journal: Circulation (2014)

Objectives: The epidemiology of patients with heart failure (HF) remains largely unexplored in some ethnicities. The aim of the current study was to examine the clinical characteristics, treatment and in-hospital outcomes of Middle Eastern Arabs and South Asian patients hospitalized with HF in a Middle-Eastern Country and compare different subsets of patients according to the degree of left ventricular (LV) dysfunction using a large national registry. Methods: Retrospective analysis of patients hospitalized with HF in Qatar from January 1991 through June 2013 was made. Patients were divided into 3 groups according to LV ejection fraction (EF) on echocardiography; HF with preserved EF (HFpEF)= EF ≥50%, HF with reduced EF (HFrEF)= EF≤40%, and (HFpEF, borderline)= EF 41-49%. Patients risk profiles, management and in-hospital outcomes were compared in the 3 groups. Results: During study period 3114 patients were hospitalized with HF; 637(20.5%) with HFpEF, 415(13.3%) with (HFpEF, borderline) and 2062(66.2%) with HFrEF. Patients with HFpEF were the oldest in age, had the highest body mass index and the highest rates of associated atrial fibrillation and valvular heart disease. Patients with (HFpEF, borderline) had the highest rates of hypertension, diabetes mellitus, chronic kidney disease, dyslipidemia, old myocardial infarction and associated acute coronary syndromes whereas patients with HFrEF had the highest rates of smokers [Table]. There were no significant differences in the length of hospital stay among the 3 groups while the in-hospital mortality was significantly highest among patients with HFrEF. Conclusions: The current study explored for the first time HF in Middle Eastern Arabs and South Asian ethnicities according to the degree of LV function. HFrEF was the commonest class accounting for two thirds of hospitalizations with HF and was associated with higher in-hospital mortality. Further studies with long term follow-up data are warranted.
Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation
Authors: Junji Yamauchi, Yoshihisa Yamano, Kenji Yuzawa
Journal: New England Journal of Medicine (2019)

HTLV-1 Infection and Kidney Transplantation A survey of kidney transplant recipients in Japan found that HTLV-1–associated myelopathy developed in 4 of 10 HTLV-1–negative patients receiving kidneys...
AB0265 Clinical predictor factors associated with sustained disease activity among patients with early rheumatoid arthritis
Authors: M.G. Gonzalez Alvarez, J. Molina, L. Nuño, V. Navarro-Compán, A. Villalba, D. Peiteado, P. Bogas, A. Balsa
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In patients with rheumatoid arthritis (RA), low disease activity (DA) overtime is associated with favourable outcomes. However, the progression of the disease is faster during the first years. Therefore, it is desirable to identify patients with a high probability of sustained DA in an early stage. <h3>Objectives</h3> To identify clinical predictor factors at diagnosis associated with sustained DA after 12 months of follow up in patients with early RA. <h3>Methods</h3> Baseline (at diagnosis) and 12 months follow-up data from an early arthritis clinic was analysed. At both visits, demographic, clinical, laboratory and treatment data were collected and clinical DA was assessed using DAS28 and SDAI. For this study, patients with RA according to physician’s diagnosis were selected. Sustained DA at 12 months was defined as DAS28 &gt;3.2 and SDAI&gt;11. Univariate and multivariable logistic regression models were employed to identify which factors are associated with sustained DA. <h3>Results</h3> In total, 566 patients were included. Out of these, 75.8% were women, 74.7% Caucasian, 77.7% RF +and 65.9% ACPA+. Mean (SD) age was 54<sup>17</sup> years and mean symptoms duration was 16<sup>15</sup> weeks. Regarding treatment, 89.8% patients received methotrexate as first line treatment and 81.1% received glucocorticoids. At baseline, 88.8% had moderate-high DA according to DAS28 (&gt;3.2) and 77.6% with SDAI (&gt;11). After one year of follow-up, 34% (DAS28) and 30.9% (SDAI) remained with moderate-high DA. Univariable logistic regression analysis results are shown in table 1. Sustained DA was significantly associated with baseline index and its individual components, HAQ, and GCs used for both indexes definitions, with smoking and MTX use for DAS28 definition and RF +for SDAI definition. In the multivariable analysis, sustained DA at 12 months remained significantly associated only with baseline DAS28 (OR 1.34; p&lt;0.05) for DAS28 definition and with RF (OR 2.6; p=0.02), HAQ (OR 1.06; p&lt;0.01) and use of glucocorticoids (OR 2.1; p&lt;0.05) for SDAI definition. <h3>Conclusions</h3> One out of three patients with RA maintains DA 12 months after diagnosis. The predictors for this status depend on the index employed: DAS28 at baseline is the best predictor for sustained disease activity when using DAS28-definition. Conversely, positive RF, impaired functionality and the need of glucocorticoids at baseline are associated with the SDAI-definition. <h3>Disclosure of Interest</h3> None declared
AB0458 Efficacy and b-cell depletion with very low dose rituximab (BIOSIMILAR) in sero-positive dmard resistant rheumatoid arthritis: a 24 week study
Authors: N.S. Jain, S. Pandya, D. Shukla, P. Srivastava
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Very Low dose Rituximab (RTX) (100 mg) has been variously used in autoimmune diseases like ITP and rheumatoid arthritis (RA). As cost of treatment is an important issue in resource poor setups, we decided to study efficacy of very low dose RTX in patients with RA. <h3>Objectives</h3> 1)To study clinical efficacy of very low dose RTX in DMARD refractory RA. 2) To study B cell depletion with very low dose RTX <h3>Methods</h3> Prospective open labelled study. Biologic naïve, conventional DMARD refractory, sero-positive RA patients ACR 2010 criteria) with high disease activity (DAS 28 ESR) were included after informed consent. Arm 1: Total 4, weekly 100 mg doses(total dose 400 mg) of a RTX biosimilar were infused. Arm 2: Single 100 mg RTX infusion. Efficacy was assessed using standard outcome measures for RA (including RAPID3) at week 24. B cell depletion (CD19 levels in peripheral blood by flow cytometry) was studied at baseline, week 1 and week 12. <h3>Results</h3> Total number of patients in Arm 1=14 and in Arm 2=13. In Arm 1: 28% (4/14) achieved EULAR remission while 78% (11/14) had EULAR good response. In Arm 2: 70% (9/13) had EULAR good response. All patients achieved complete B-cell depletion(defined as &lt;0.01%) at week 1 after just single dose of 100 mg RTX remained so at 6 weeks only to start rising again at week 12. There were no adverse events noted. Steroid doses were reduced in most patients at follow up visits with delta change in steroid dose- 2.2 mg/day. Results comparable with other studies using both low dose and conventional dose of RTX. Limitations of the study includes small sample size and short follow-up. <h3>Conclusions</h3> Very Low dose RTX is efficacious in conventional DMARD refractory RA patients. Single dose (100 mg) is as good as 400 mg upto week 24. Complete B cell depletion can be achieved even with 100 mg RTX as early as week 1. <h3>References</h3> [1] Bavaliya, et al. Efficacy of very low dose (100 mg) rituximab in active Rheumatoid arthritis despite combinations DMARDs, Annal of Rheumatic Diseases. [2] Chatzidionysiou et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Research &amp; Therapy 2016. [3] Ravindran et al. Efficacy and safety of biosimilar rituximab in biologic naive patients with rheumatoid arthritis: a single centre experience from kerala, india; Rheumatology (Oxford) 2015. <h3>Disclosure of Interest</h3> None declared
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Authors: Wilbert S Aronow, Jerome L Fleg, Carl J Pepine, Nancy T Artinian, George Bakris, Alan S Brown, Keith C Ferdinand, Mary Ann Forciea, William H Frishman, Cheryl Jaigobin, John B Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W Rich, Douglas D Schocken, Michael A Weber, Deborah J Wesley
Journal: Journal of the American College of Cardiology (2011)
Abstract 17223: Fetal Hemodynamics Predict Postnatal Regional and Microstructural Brain Alterations in Complex Congenital Heart Disease
Authors: Jodie K Votava-Smith, Jay D Pruetz, Nhu Tran, Vincent Lee, Hollie Lai, Vincent J Schmithorst, Lisa B Paquette, Ashok Panigrahy
Journal: Circulation (2017)

Introduction: Congenital heart disease (CHD) is associated with brain abnormalities and injury. Cerebrovascular redistribution is common in fetal CHD but of unclear significance. We aimed to determ...
THU0225 The progression of lung involvement in rheumatoid arthritis patients receiving biological therapies
Authors: Y. Yalçınkaya, M. Can, S. Karakurt, N. Coşkun, E. Albayrak, H. Mursaloglu, A. Topcu, M. Demir, E. Dalkılıc, N. Inanc
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Lung involment is one of the extra-articular manifestations that is shown to be related to morbidity and mortality in Rheumatoid arthritis (RA). <h3>Objectives</h3> We evaluated the progression of lung involvement in RA patients receiving biological treatment. <h3>Methods</h3> Eighty RA patients fulfilling ACR/EULAR classification criteria (2010) receiving biologics who had high-resolution computerised tomography (HRCT) of chest within 6 months of respiratory symptoms (cough/dyspnea) and/or any pathology in chest radiography were included. Warrick score, evaluating alveolitis and fibrosis, was calculated in RA patients by using HRCT of chest. <h3>Results</h3> The demographics and clinical findings were summarised in table 1. In 29 RA patients with interstitial findings in HRCT of chest; 7 (24%) were regressed and 1 (4%) was progressed with biologic drugs. Findings of alveolitis and fibrosis were completely regressed in 2, only alveolitis component was completely regressed in 3 and partially in 2 patients. The patient who progressed had new findings of alveolitis (table 2). Twenty-one patients in whom Warrick scores did not change, 5 received rituximab (RTX) and 10 received TNF inhibitors (TNF-inh). The mean Warrick scores was improved after biologics (11,3±9 (3–30) vs 10,3±9 (0–30), p=0,035). The improvement in alveolitis scores was significant (2,1±1,6 vs 1,5±1,6, p=0,031) while fibrosis scores were not (9,2±7,7 vs 8,8±8). Initial and control Warrick scores were higher in RTX receivers (16±9 vs 9,2±8, p=0034 and 14,8±10,1 vs 8,4±8,1), but the improvement after biologics was not different. <h3>Conclusions</h3> This study revealed an improvement in alveolitis after biologic drugs in RA patients. Fibrosis was not found to be effected by therapy. Lung lesions were improved in both RTX and TNF-inh groups. <h3>Disclosure of Interest</h3> None declared
SPARC promoter hypermethylation in colon cancer and the effect of 5-Aza-2’deoxycytidine in enhancing SPARC gene expression and therapy sensitivity.
Authors: Sonia Cheetham, Farnaz Taghizadeh, David Owen, Felix Mesak, Isabella Tai
Journal: Cancer Research (2007)

2888  SPARC is a matricellular glycoprotein that has variable expression in many types of cancers. Its expression may be dependent on epigenetic mechanisms, as hypermethylation of the SPARC promoter accounts for loss of SPARC gene expression in pancreatic and lung cancers. Our laboratory previously observed a decrease in SPARC in colorectal cancers (CRC) and showed an inverse correlation between low levels of SPARC and chemotherapy sensitivity. These observations led us to wonder if a similar epigenetic effect may be at play, and whether a therapeutic strategy using demethylating agents may enhance SPARC expression and improve therapy sensitivity in CRC. Therefore, theAIM of this study was to determine if methylation of the SPARC promoter is a potential mechanism responsible for decreased SPARC expression in CRC. METHODS: DNA extracted from CRC cell lines (MIP 101, RKO, HCT 116, and HT29) underwent bisulfite treatment prior to the determination of SPARC promoter methylation status using methylation-specific PCR (MSP). The effect of SPARC promoter methylation on gene expression, and cell viability following exposure to 5-Aza-2’deoxycytidine (5-Aza), a demethylating agent, in combination with 5-Fluorouracil (5-FU) was also assessed. Our preliminary RESULTS demonstrated hypermethylation in MIP101 and RKO cells in the entire region spanning the SPARC promoter, but incomplete methylation in HCT 116 and HT29 cells was observed. Evaluation of a limited number of clinical samples of CRCs revealed that in 33% of cases, SPARC promoter methylation was present. These results suggest that in a subset of CRCs, SPARC promoter hypermethylation may contribute to repressing its transcription. This methylation status could be reversed in all four cell lines following exposure to 8 µM 5-Aza, with concomitant increases at the transcriptional level. Furthermore, in HCT 116 cells, a significant decrease in cell viability could be observed following incubation of 5-Aza and 100µM of 5-FU in comparison to 5-FU alone: from 99.6%+ 5.3viable cells (5-FU treated only) to 77.4% + 8.1. In CONCLUSION, SPARC promoter methylation may play a role in the transcriptional downregulation of SPARC in CRC, and the addition of a demethylating agent that upregulates SPARC expression may be a useful adjunct in the treatment of CRC.
Abstract 15545: Long-term Impact of a Hospital-based Discharge Medication Program Designed to Assure Appropriate Utilization of Statin Therapy in Patients Hospitalized With a New Diagnosis of Coronary Artery Disease (CAD) Within a Large Integrated Healthcare Institution: A Significant Treatment Gap Still Remains: The IMPRES Study
Authors: Joseph B Muhlestein, Donald L Lappé, Kirk U Knowlton, Heidi T May, Tami L Bair, Jeffrey L Anderson
Journal: Circulation (2017)

Introduction: In 1999, Intermountain Healthcare initiated an ongoing hospital-based discharge medication program (DMP) designed to ensure that all patients admitted with heart disease (including CA...
Evidence Based Recommendations for Supportive Care in Multiple Myeloma
Authors: Anum Qureshi, Muhammad Junaid Tariq, Zunairah Shah, Muhammad Abu Zar, Shehroz Aslam, Abdul Rafae, Mustafa Nadeem Malik, Ahmad Kamal, Jemin Aby Jose, Insija Ilyas Selene, Madeeha Shafqat, Faiza Jamil, Seren Durer, Ceren Durer, Faiz Anwer
Journal: Blood (2018)
OP0310 Prevalence of risk factors and cardiovascular events across psoriatic arthritis patients treated with biological therapy
Authors: F. Maceiras-Pan, C. García-Porrúa, J.A. Mosquera-Martinez, L. Fernandez-Dominguez, B. Correa-Rey, M. Pombo-Suarez, J. Pinto-Tasende
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Psoriasis and psoriatic arthritis (PsA) are described as associated with more frequency of risk factors and cardiovascular events. <h3>Objectives</h3> To determine the prevalence of risk factors and cardiovascular events in a cohort of patients with PsA treated with biological therapy and its correlation with gender. <h3>Methods</h3> We included all PsA patients (met CASPAR criteria) following treatment with bDMARDs (reference population 2.055.000). We obtained data of high blood pressure, hyperlipidemia, hyperuricemia, type 2 diabetes mellitus, obesity (BMI ≥30), non-infectious liver disease, ischaemic cardiopathy, myocardial infarction, ischaemic stroke or transient ischaemic attack. For this analysis included gender, age, disease duration, current bDMARDs with or without current co-medication with csDMARDs and HLA-B27 status. Continuous variables were reported as mean ±standard deviation. Categorical variables were reported as percentages and frequencies. All analyses were performed using SPSS software. Differences were considered statistically significant if p&lt;0.05 (two-tailed). <h3>Results</h3> Data were obtained from 598 PsA patients who have been treated with bDMARDs. Three-hundred and twenty-five (54.3%) patients were men, mean age was 53.3±12.6 years (men 53.3±12.9 and women 53.2±12.3, p=0.943) and disease duration of PsA was 12.4±8.7 years. No differences were seen for disease duration of PsA, nail disease, dactylitis, uveitis or HLA-B27. The prevalence of high blood pressure, hyperlipidemia, hyperuricemia, type 2 diabetes mellitus, obesity, non-infectious liver disease, ischaemic cardiopathy, myocardial infarction (MI) and ischaemic stroke/transient ischaemic attack (IS) was 36.0%, 43.6%, 16.0%, 12.5%, 26.3%, 12.5%, 5.5%, 3.8% and 1.3%, respectively. Men had most prevalence of type 2 diabetes mellitus, hyperuricemia, non-infectious liver disease, ischaemic cardiopathy, myocardial infarction and brain stroke event (see table 1). Patients with MI or IS had more prevalence of CV risk factors. <h3>Conclusions</h3> Type 2 diabetes mellitus, hyperuricemia, non-infectious liver disease, ischaemic cardiopathy, myocardial infarction and brain stroke event were more prevalent in men than in women with PsA. Male gender had correlation with the prevalence of cardiovascular events or their risk factors. <h3>Reference</h3> [1] Husted JA, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care Res (Hoboken)2011Dec;63(12):1729–35. <h3>Acknowledgements</h3> The authors are grateful for the support of the members of the Galician Society of Rheumatology (SOGARE) <h3>Disclosure of Interest</h3> None declared